Navigation Links
K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity
Date:5/25/2012

ed Makena® acquisition agreement, as amended from time to time, including $95.0 million of remaining scheduled payments by us for those rights; and

(e)    the number of preterm births for which Makena® may be prescribed, its safety and side effects profiles and acceptance of pricing;

(3)    the possibility of delay or inability to obtain FDA approvals of Clindesse® and Gynazole-1® and the possibility that any product relaunch may be delayed or unsuccessful;

(4)    risks related to compliance with various agreements and settlements with governmental entities including those discussed in Item 1 (b)— "Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decree" in the Company's Form 10-K/A for the fiscal year ended March 31, 2011 (the "Fiscal 2011 Form 10-K/A) or in our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2011, including:

(a)    the consent decree between the Company and the FDA and the Company's suspension in 2008 and 2009 of the production and shipment and the nationwide recall of all of the products that it formerly manufactured, as well as the related material adverse effect on our revenue, assets, liquidity and capital resources;

(b)    the agreement between the Company and the Office of Inspector General of the U.S. Department of Health and Human Services ("HHS OIG") to resolve the risk of potential exclusion of the Company from participation in federal healthcare programs;

(c)     our ability to comply with the plea agreement between a now-dissolved subsidiary of the Company and the U.S. Department of Justice; and

(d)    our ability to comply with the Settlement Agreement dated December 7, 2011 with the United States resolving certain claims under the Qui T
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Specialty Coating Systems is ... Parylene coating technologies: SCS microRESIST™ Antimicrobial Parylene ... Parylene with antimicrobial properties to effectively eliminate ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... and continue to pose a challenge to ...
(Date:6/18/2013)... 18, 2013 MPR is excited to unveil ... edition. It,s all part of an ongoing effort to freshen ... practitioners for over 28 years. (Photo: ... evolution MPR has expanded upon its foundation as ... to include an increasing array of clinical and practice management ...
(Date:6/18/2013)... INDIANAPOLIS , June 18, 2013 The ... LLY ) has declared a dividend for ... on outstanding common stock. The dividend ... at the close of business on August 15, 2013. ... a growing portfolio of pharmaceutical products by applying the ...
Breaking Medicine Technology:Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2MPR Sports a Bold New Look 2
... ® Products is pleased to announce ... was developed to support the recent introduction of LimbO Waterproof Protectors ... Products in the United Kingdom, LimbO Waterproof Protectors enable children and ... cast or a bandage. The waterproof cover is simply slipped on ...
... CITY, Feb. 21, 2012 Genomma Lab Internacional, S.A.B. de ... a non-binding proposal to acquire all of the outstanding shares ... ) common stock for $16.60 dollars per share in cash. ... including Prestige,s net debt. Genomma,s all-cash proposal ...
Cached Medicine Technology:LimbO® Products Launches New U.S. Website 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 3Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 4Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 5
(Date:6/18/2013)... 2013 Senior drug regulatory officials from mainland ... to discuss—for the first time in the U.S.—the need for ... the regulatory process in a timely manner. Representatives from the ... respective best practices and processes in drug review during the ... at the DIA 2013 49th Annual Meeting . ...
(Date:6/18/2013)... Seven-year-old Riley Salz of Encino, California, is ... 40 hours a week of applied behavior analysis (ABA) ... for Autism and Related Disorders (CARD). Riley has been ... experienced remarkable progress, including learning to speak, starting conversations, ... journey through autism is now featured in CARD’s “Mission ...
(Date:6/18/2013)... have discovered and mapped the signaling network between two ... could cut off cancer cell growth at its starting ... University of Texas MD Anderson Cancer Center reported the ... cancer drug target, and MCM7, a protein vital to ... issue of Cancer Cell . , "MCM7 overexpression ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from respiratory ... of a silicone treatment for gluteus augmentation at Cuerpos Health ... by a mystery Venezuelan doctor in a center that was ... Vazquez of Bayshore Cosmetic Surgery , women suffering from ... not board certified is more common than people think. ...
(Date:6/18/2013)... 18, 2013 David Connett, DO, vice ... Medicine for the College of Osteopathic Medicine of the ... been elected president of the Osteopathic Medical Board ... Jr. appointed Connett, a 1984 alumnus of COMP, to ... elected Connett to the position during a conference call. ...
Breaking Medicine News(10 mins):Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... China should focus on providing affordable medical care for the ... the wealthy minority, the country's health minister said.// ... medical equipment, trying to keep pace with developed countries, and ... Qiang said at a national health conference Saturday, says a ...
... in-hospital cardiac arrests than adults; with appropriate cardiopulmonary resuscitation ... previously thought.// ,These are some findings of ... supervised by Robert A. Berg, MD, professor of pediatrics ... of Medicine. ,The study results have been ...
... Union Minister for Health and Family Welfare, announced that the ... phase of the Reproductive and Child Health Programme called RCH-II.// ... All India Congress of Obstetrics and Gynaecology in Kochi yesterday. ... sector was to reduce the Maternal Mortality Rate, which was ...
... be maintained by a low fat diet into old age, ... counting is unnecessary. The study on nearly 50,000 post-menopausal women ... of the American Medical Association (JAMA), comes to the conclusion ... daily calories was enough to maintain a stable weight. ...
... revealed that more devastating earthquakes are likely to take place ... // They will inflict far greater damage than the 8 ... Bilham who has been working in quake-affected areas of Pakistan ... of energy was stored in the fault line in the ...
... (FOBT) is a simpler way of identifying individuals who ... published online in The Lancet Oncology.// Conventionally, guaiac FOBT ... this cancer, but this new test "could decrease substantially ... for colorectal cancer." ,Lead author Dr Callum G ...
Cached Medicine News:Health News:After Cardiac Arrest, Children Fare Better Than Adults 2Health News:More Severe Earthquakes May Hit Kashmir In Future 2
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
The link classic plus hip stem for cemented primary hip replacement surgery...
The uncemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
Medicine Products: